过去一年中添加的文章，按日期排序
Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors.
Z Miao, F Lin, X Rao, Y Huang, F Wang, Y LU, X Huang… - 2024 - ascopubs.org
28 天前 - … Conclusions: ZV0203 was well tolerated and showed clinically encouraging anti-tumor
activity in heavily pretreated pts with HER2 positive cancer. Clinical trial information: …
activity in heavily pretreated pts with HER2 positive cancer. Clinical trial information: …
First-line sintilimab combined with platinum-based chemotherapy in extensive stage small cell lung cancer: A phase II study and post-hoc biomarker analysis.
CX Su, M Xie, J Zhao, X Chu, L Liu - 2024 - ascopubs.org
28 天前 - … The primary endpoint of this study is progression-free survival (PFS), with patients
being defined as disease progression according to RECIST 1.1. Pre-treatment FFPE samples …
being defined as disease progression according to RECIST 1.1. Pre-treatment FFPE samples …
Exploring the safety and efficacy of GT201 as a first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors.
Z Han, W Fang, K Chen, Y Chen, H Wang, J Tang, J Yu… - 2024 - ascopubs.org
28 天前 - … across various indications, including Non-Small-Cell-Lung Cancer (NSCLC), …
Conclusions: In patients with heavily pretreated advanced or metastatic solid tumor, GT201, when …
Conclusions: In patients with heavily pretreated advanced or metastatic solid tumor, GT201, when …
Comprehensive analysis of the value of dynamic changes in ctDNA in SCLC.
P Joseph, Z Chen, A Ajay, P Fu, A Dowlati - 2024 - ascopubs.org
28 天前 - … lung cancer (… pretreatment to remission (comparing those with a > or < 99% decrease)
also did not associate with OS, PFS, or DFS. Patients with RB1 alterations at pretreatment …
also did not associate with OS, PFS, or DFS. Patients with RB1 alterations at pretreatment …
Single-cell landscape of the immune microenvironment of leptomeningeal metastases in non-small cell lung cancer treated with pemetrexed sheath injection.
Y Xu - 2024 - ascopubs.org
28 天前 - … and cancer cells with decreased significantly after pemetrexed injection. The cancer
cells in … receiving pemetrexed sheath treatment than pre- treatment, which was validated by …
cells in … receiving pemetrexed sheath treatment than pre- treatment, which was validated by …
Therapeutic stratification for small cell lung cancer with multiplexed proteomic analysis.
TJ Kim - 2024 - ascopubs.org
28 天前 - … therapy, most patients with small-cell lung cancer (SCLC) … Pre-treated SCLC
patients can opt for clinical trials of … To assess the proportions of patients who would be likely …
patients can opt for clinical trials of … To assess the proportions of patients who would be likely …
Prevention of pemetrexed-induced rash with low-dose dexamethasone in patients with NSCLC receiving immunotherapy: A prospective, single-arm clinical trial.
J Zhang, X Zhou, Y Jia, S Huang, Q Wang, MQ Jiang… - 2024 - ascopubs.org
28 天前 - … Background: Pemetrexed is highly active in non-small cell lung cancer (NSCLC). …
in pretreatment of pemetrexed-induced rash, particularly in NSCLC patients receiving …
in pretreatment of pemetrexed-induced rash, particularly in NSCLC patients receiving …
Effects of pre-treatment on odds of immune-related adverse events.
J Hunting, E Olson, AT Faucheux, CA Elko, MP Knapp… - 2024 - ascopubs.org
28 天前 - … and second-, third-, or at least fourth-line in 1,119, 328, and 222 patients,
respectively. The most common tumor type was non-small cell lung cancer (36%), followed by …
respectively. The most common tumor type was non-small cell lung cancer (36%), followed by …
Efficacy and safety of PD-1 inhibitors plus metronomic oral vinorelbine in elderly pre-treated patients with metastatic non-small-cell lung cancer.
L Li, Y Yuan, J Gao, P Zhang, X Wu, M Tang, X Nie… - 2024 - ascopubs.org
28 天前 - e20556 Background: The subsequent therapy of elderly non-small cell lung cancer
(NSCLC) without driver oncogene has always been a challenge due to the poor …
(NSCLC) without driver oncogene has always been a challenge due to the poor …
Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A …
28 天前 - … Pretreatment interstitial lung abnormalities (ILAs) are associated with partial
resolution of ICI pneumonitis, which in turn is associated with new or worsening pulmonary and …
resolution of ICI pneumonitis, which in turn is associated with new or worsening pulmonary and …